Journal of Medical Physics
 Home | Search | Ahead of print | Current Issue | Archives | Instructions | Subscription | Login  The official journal of AMPI, IOMP and AFOMP      
 Users online: 310  Home  EMail this page Print this page Decrease font size Default font size Increase font size 

 Table of Contents    
Year : 2012  |  Volume : 37  |  Issue : 4  |  Page : 207-213

Homogeneity Index: An objective tool for assessment of conformal radiation treatments

Division of Radiation Oncology, Medanta Cancer Institute, Medanta- The Medicity, Sector- 38, Gurgaon, Haryana, India

Date of Submission17-Mar-2012
Date of Decision01-Jul-2012
Date of Acceptance17-Jul-2012
Date of Web Publication20-Nov-2012

Correspondence Address:
Tejinder Kataria
Division of Radiation Oncology, Medanta Cancer Institute, Medanta- The Medicity, Sector- 38, Gurgaon - 122 001, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-6203.103606

Rights and Permissions



Homogeneity Index (HI) is an objective tool to analyz the uniformity of dose distribution in the target volume. Various formulae have been described in literature for its calculation but there is paucity of data regarding the ideal formula and the factors affecting this index. This study was undertaken to analyze HI in our patients using various formulae and to find out the co-relation between HI and prescribed dose, target volume and target location. A retrospective review of 99 patients was performed. HI was calculated using five different formulae (A-E). The patients were divided in five groups each, based on prescribed dose, target volume and target location and mean HI of each group was analysed to find the co-relation between these factors and HI. When there were multiple target volumes the primary target volume was studied. The statistical calculation was done using SPSS version 16.0. Ninety nine patients were found evaluable with 75 males and 24 females. Ninety five patients were treated with radical intent and four with palliative intent. The sites treated were head and neck (46.4%), Pelvis (17.1%), brain (15.1%), abdomen (12.1%), and thorax (6.1%). The mean prescribed dose was 4304 cGy (centiGray) and the mean target volume was 476.2 cc. The mean value of HI was 1.21, 2.08, 30.13, 21.51 and 1.27 with different formulae. There was considerable agreement between HI calculated using various formulae specially the formulae considering prescribed dose (C, D). On statistical analysis, there was no significant co-relation between the location and volume of target but there was a trend toward better HI with increasing prescribed dose. Future studies with more number of patients can confirm our results.

Keywords: Dose, factors, formulae, homogeneity, index, radiotherapy

How to cite this article:
Kataria T, Sharma K, Subramani V, Karrthick K P, Bisht SS. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys 2012;37:207-13

How to cite this URL:
Kataria T, Sharma K, Subramani V, Karrthick K P, Bisht SS. Homogeneity Index: An objective tool for assessment of conformal radiation treatments. J Med Phys [serial online] 2012 [cited 2023 Feb 1];37:207-13. Available from:

   Introduction Top

In radiotherapy, since its inception, the objective has always been to deliver maximum dose to the target volume homogeneously, while avoiding dose to the normal surrounding structures. Progress made in last few decades in medical imaging and dosimetric software has allowed us to achieve this objective by visualization of the spatial dose distribution within the target volumes. As a result of these developments, various treatment plans can now be easily and rapidly obtained for the same patient. The dose distribution in these plans can then be visualized in the form of dose-volume histograms (DVHs) and isodose lines, to define parameters like maximum dose (D max ), minimum dose (D min ), mean dose (D mean ) and modal dose delivered to each volume of interest. Unfortunately, the large volume of data contained in these histograms, lines and curves may complicate the problem rather than simplifying it. This makes it desirable to have a tool that can integrate this data in a simpler way to quantitatively assess the quality of the treatment plan options. By using such a tool we can make a choice in favor of a plan which provides maximum tumor coverage homogeneously and protects healthy tissues at the same time. The homogeneity index (HI) and the conformity index (CI) are two such tools for treatment plan analysis in conformal radiotherapy.

The concept of HI was developed as an extension of section-by-section dosimetric analysis of treatment plans. In 1993, the Radiation Therapy Oncology Group (RTOG) proposed guidelines for routine evaluation of stereotactic radiotherapy (SRT) plans based on several parameters and HI was described as, HI RTOG = I max /RI, where, I max = maximum isodose in the target, and RI = reference isodose. If the HI was ≤2, treatment was considered to comply with the protocol, if this index was between 2 to 2.5, it was considered as minor violation, but if the index exceeded 2.5, the violation of the protocol was considered to be major, but might nevertheless considered acceptable. [1],[2]

Certain other definitions were later described, for example HI = D 5 /D 95 ; where D 5 = minimum dose in 5% of the Planning Target Volume (PTV), indicating the "maximum dose", and D 95 = minimum dose in 95% of the PTV, indicating the "minimum dose". The lower (closer to one) the index, the better is the dose homogeneity. [3]

A more descriptive formula is HI = D 2 -D 98 /D p ×100; where D 2 = minimum dose to 2% of the target volume indicating the "maximum dose", D 98 = minimum dose to the 98% of the target volume, indicating the "minimum dose" and D p = prescribed dose. This is the most commonly used formula in the literature. The reason for choosing D 98 and D 2 , to represent the minimum and maximum dose, is that the calculation of true minimum or maximum dose is sensitive to the dose-calculation parameters, such as grid size and grid placement, and the high dose gradient is common in Intensity Modulated Radio-Therapy (IMRT). Therefore, the true minimum or maximum dose is typically not reliable. [4] This is the reason for choosing the maximum or minimum dose in a volume (D 2 , D 98 etc.) rather than at a point. Thus, in all definitions, HI basically indicates the ratio between the maximum and minimum dose in the target volume and the lower value indicates a more homogenous dose distribution within this volume.

Although, various definitions and formulae have been described in literature by various authors and organizations, none has been described as ideal or near ideal for calculating HI. Moreover, less emphasis has been given to this parameter as compared to other treatment planning parameters. For example; several combined indices for evaluating dose coverage, conformity, and dose gradient together have been suggested in the past but, none of these incorporate dose homogeneity as their component. [5],[6],[7],[8],[9] In addition, there is a paucity of data in literature regarding the factors that influence HI and the extent of such influence. A search for these factors can enhance our understanding regarding HI, which will allow us to better analyze the spatial dose distribution in our treatment plans. This in turn, will help us to find the means by which we can improve upon our treatment plans in future.

In the present study, we reviewed various definitions/formulae of HI that have been described in literature. [1],[2],[3],[4] We have used these formulae to calculate the HI of each patient and have tried to analyze the concordance level between values of HI obtained with each formula. We also analyzed the association between the HI and the prescribed dose, volume of the target, and location of target in the body.

   Materials and Methods Top

We performed a review of 99 patients treated for tumors located in different regions (locations) of the body. All the plans were created according to the clinical protocol followed in the department without any deviation. A CT (Computed Tomography) scan based radiographic volume data set was used for the definition of target volumes, organs at risk, and other structures of interest. The target volumes like Gross Tumor Volume (GTV), Clinical Target Volume (CTV) and PTV were defined as per their definitions in International Commission on Radiation Units and Measurements (ICRU) Report 50. [10]

The treating radiation oncologist determined the target volumes and the treatment dose. In most cases, the planning was done with the following aims: minimum dose greater than or equal to 95% and the maximum dose less than or equal to 107% of the prescribed dose. The normalization of each plan followed the recommendation of ICRU report 50. The ICRU point was used for normalization and was set at 100%. This point dose was also the prescribed dose, resulting in a dose variation across the target from 95% to 107% of the prescription dose in most cases. The target volume selected for calculating the HI was PTV. In cases, where two or more target volumes were present, the primary/larger target volume was selected for analysis. The leaf edge to PTV distance (target margin) was kept 7 mm in all cases. The DVH of each plan was generated and it was evaluated by radiation oncologist along with medical physicist until an acceptable plan was obtained.

The HI was calculated using the five different formulae given below.

Formula A : D 5 /D 95 ; where D 5 = minimum dose in 5% of the target volume and D 95 = minimum dose in 95% of the target volume. The ideal value is 1 and it increases as the plan become less homogeneous. [11]

Formula B: D max /D min ; where D max and D min represent the maximum and minimum point dose in the target volume, respectively. This formula has not been used in literature but it represents the classical definition of HI i.e., the ratio of maximum and minimum dose. This formula was used to represent the philosophy behind the definition of HI. It may not be technically correct to use this formula in practice as the doses may be very high or very low, if only point doses are considered. The ideal value is 1 and it increases as the plan becomes less homogeneous.

Formula C: D 1 -D 98 /D p× 100; where D 1 and D 98 are the minimum dose in 1% and 98% of the target volume and D p is the prescribed dose. This is the formula used for calculating HI in our department which is a slight modification of the formula (D 1 instead of D 2 making it more sensitive) described by Wu, et al. [4] The ideal value is Zero and increase as homogeneity decreases.

Formula D: D 5 -D 95 /D p×100; where D 5 and D 95 are the minimum dose in 5% and 95% of the target volume and D p is the prescribed dose. The ideal value is zero when D 5 and D 95 are equal. This formula is also a modification of formula by Wu et al., where D 2 and D 98 has been replaced by D 5 and D 95 . [4]

Formula E: D max /D p ; where D max is the maximum point dose and D p is the prescribed dose to the target volume i.e., the prescription isodose line chosen to cover the margin of the tumor. [8],[12] This was first described by RTOG and the ideal value is 1.

The patients were then divided into five groups, based on the prescribed dose for treatment, volume of target and the location of the target. This resulted in 15 different groups. The mean HI was calculated for each group using all the formulae. The data was then analyzed to find out the relationship between HI and various parameters like prescribed dose, target volume and location of the target (CTV or PTV).

The data was compiled using microsoft excel software and mean and median values of HI were calculated using statistical methods. Pearsons Chi-square test (SPSS Vs 16.02) was used to test the association between the mean value of HI calculated by a particular formula and the prescribed dose, volume of target and the location of target in the body. The same test was performed separately for each group using one formula at a time.

   Results Top

On final analysis of data, there were 75 males and 24 females. These patients received radiation for different diagnoses including head and neck carcinomas (46.4%), brain tumours (15.1%) and other malignancies. Most of the patients i.e., 95.9% were treated with radical intent while others were treated for palliation. Detailed descriptive data of the patients is presented in [Table 1].
Table 1: Patient's characteristics

Click here to view

The minimum, maximum, mean and median value of HI was calculated using different formulae (A, B, C, D and E) for all the patients collectively, as shown in [Table 2]. Since it was a retrospective study, few of the values (D 5 or D 95 ) required for calculating HI were not recorded in 33% of all the patients. Thus, formulae A and D could be applied in 67 and 66 patients, respectively. All other formulae were applied in all the patients.
Table 2: Values of HI calculated using different formulae

Click here to view

Analysis of minimum HI (best homogeneity) by all formulae revealed that, four (A, C, D, E) out of five formulae showed this value in the same patient. The patient was a case of carcinoma prostate (Pelvis) with prescription dose of 2414 cGy (centiGray) for a boost volume of 268.2 cc. This shows the level of agreement or concordance among various formulae. The same trend however, could not be observed while analyzing the maximum value of HI in similar manner. The maximum value of HI was seen in different patient by each formula.

The dose prescription varied from 1600 cGy to 7000 cGy. The overall mean and median prescribed dose was 4304 cGy and 4500 cGy, respectively. This large variation is explained by the fact that many patients were planned for IMRT boost (following the initial treatment with conventional or 3-Dimensional conformal radiotherapy) or palliative radiation requiring lesser dose. The patients were divided into five groups according to prescribed dose and mean HI for each group was calculated using formulae A to E. The resulting values of HI are shown in [Table 3].
Table 3: Values of HI according to the dose prescribed for treatment

Click here to view

According to dose, the lowest values of HI (best homogeneity) were seen in the group receiving highest dose i.e., 6000 cGy or more, by all the formulae. Similarly, the highest values of HI were seen in first two groups i.e., 4000 cGy or less. This again shows the high level of agreement between various formulae and suggests a trend towards improved HI as the prescribed dose increases. When analysed statistically, significant difference in HI was found between the group using formulae A, C and D. The other formulae could not reach a significant value.

When target volume data was analyzed, volume of the target varied from 84.2 cc to 2247 cc, with a mean and median value of 476.2 cc and 360 cc, respectively. The patients were divided into five groups according to the volume of targets and mean HI for each group was calculated using formula A to E [Table 4].
Table 4: Values of HI according to the target volume

Click here to view

When analyzed in detail, the lowest values (best homogeneity) of HI by all the formulae were seen in group having the lowest target volume i.e., 400 cc or less. On the other hand, the highest HI was seen in last two groups (1201 cc or more) by all formulae except formula B. This indicates a reasonable level of agreement or concordance between different formulae except formula B. This observation suggests a trend towards worsening of HI as the target volume increases. When this observation was statistically analysed, no statistically significant difference in HI was found between the groups with different target volume.

When divided into groups depending on the location of the target in the body, the maximum number of patients (49.5%) were in the head and neck group (49.5%), followed by pelvis (17.1%) and others. The exact distribution of patients according to location and the mean values of HI using various formulae are shown in [Table 5].
Table 5: Values of HI according to the location of the target

Click here to view

The brain cases were found to have the highest value by all the formulae. In contrast, the best HI was observed in cases of abdomen (formula A, D) and thorax (B, C, E). The value of HI in head and neck and pelvic tumors were lying in-between. This shows the level of agreement among various formulae used for calculating HI. On statistical analysis, no statistically significant association was found between the location of the target in the body and the HI.

   Discussion Top

HI is a good indicator of pattern of dose distribution in a target volume but it is still unclear that what are the factors influencing this index. In literature, few studies have been done correlating treatment parameters like target location or target volume with treatment plan indicators like HI or CI. Knoos et al., in their evaluation of Radiation Conformity Index (RCI) found a better conformity for cases with pelvic tumors as compared to those of lung and advanced breast cancer cases. The same authors found improvement in the value of RCI with increasing volume of PTV in breast cancer group but no such correlation between the RCI and volume of PTV was seen when all patients were studied together. [13] Similarly, Wu et al. found that esophageal and lung cancer cases were easier to conform than the nasopharyngeal and prostate cancers. [14]

Collins et al., studied the relationship of variables like shape, size and complexity of skull base tumors with parameters like new CI, HI, and percentage tumor coverage using cyberknife radiosurgery system. They found that these radiosurgical parameters using cyberknife were independent of these tumor variables. [11] In another study, to evaluate the association of Conformity Distance Index with the size and shape of the target volume, Wu et al. found that both volume and shape complexity can have significant effects on conformity values. They found that conformity indices tend to have inferior values for smaller or more complex targets as compared to those with larger volumes or simpler shapes. [15] All these studies were more focused on analyzing the conformity rather than homogeneity indices. In our analysis, we have focused ourselves to the HI and found a trend towards improved homogeneity as the target volume reduces and vice-verse.

In our analysis, the correlation between HI and prescribed dose was a novel idea. It showed a trend towards improved HI with increasing value of prescribed dose. These values also reached near statistical significance in some cases. The reason for this trend is the fact that in cases with lower prescribed dose; even a slight variation of dose across the target volume became significant in relation to the prescribed dose. An important point is the fact that formula B did not show any significant correlation with dose as this does not take into account the prescribed dose unlike formula C, D, and E which seems to be more sensitive to the change in the dose values. Thus, the formulae which consider the prescribed dose seem to be more sensitive while calculating HI.

In our study, best HI was found in thoracic and abdominal cases while inferior values were seen in brain tumors. These finding may be a reflection of various other factors rather than the mere location of the target. Since, in our study, the prescribed dose was lower in case of brain lesions as in many cases it was the IMRT boost, the inferior HI could be a reflection of the lower prescribed doses.

Utility of homogeneity index

The radiation oncologist, while evaluating a plan has to consider clinical, biologic, geometric, dosimetric and radiologic parameters at the same time, which is an essential but complex and time consuming process. As described above, HI can facilitate by providing an objective measure of the homogeneity, which is an important quality indicator for a plan.

Often, radiation oncologist is provided with various plans for the same patients and making a choice becomes difficult in the absence of objective parameters. HI along with other indicators can be used to choose the best plan among available options.

This tool can also be used to compare various devices or techniques. For example, the dosimetric studies of ellipsoid phantoms have shown that the cyberknife radiosurgical system has the best homogeneity within the target volume as compared to other radiosurgical devices like gamma knife, linear accelerator based stereotactic radiosurgery systems with multiple arcs or IMRT. [16] Thus, it can serve as a guide for development of future strategies, technology and treatment protocols.

Assessment of results in radiotherapy requires time for data to mature. But treatment planning parameters like homogeneity index can be assessed much earlier to guide the quality of a plan. [12]

Limitation of homogeneity index

The multiple indices proposed in the literature, as well as the difficulty in their interpretation, raise a number of issues regarding the utility and credibility of this tool. Moreover, there is limited information regarding possible correlation between clinical data and these theoretical parameters. Theoretically, improvements in the homogeneity or conformity should improve local control and decrease complications but there are no studies till date which suggest that the plans with a better HI are associated with a better clinical outcome as compared to those plans with inferior HI. Chang et al. in their study suggested that improved dose homogeneity and a staged treatment regimen may improve hearing preservation in patients receiving SRS for acoustic neuroma. [17]

At the present time, only geometric and dosimetric data is incorporated while calculating or analyzing these indices. Since various radiobiological parameters like tumor control probability (TCP) and normal tissue complication probability (NTCP) and Equivalent Uniform Dose (EUD) have been incorporated in the treatment planning systems, there is a need to incorporate them in defining HI. Recent studies have suggested that somewhat greater dose heterogeneity in target volumes is expected by using biological cost functions for treatment planning. [18] Integration of these probabilistic data in calculation of quality indicators will allow us in selection of a treatment plan on the basis of radiobiologic characteristics of the target tissues rather than merely the physical doses and volumes.

Cautions while using HI

Planning indicators like HI depend upon the particular formula which is being used for its calculation. So, attention is required while calculating it. For example, when comparing different treatment plans or different irradiation techniques, it is important to use the same formula. It is emphasized to clearly specify the target volume, to which the homogeneity index corresponds, because depending on the choice of tumor volume (CTV or PTV) and the margins used, the results can vary considerably, leading to erroneous conclusions. [8] In our study, we have considered PTV in all the cases.

It is not always justified to try for achieving the ideal value of HI at any cost. There are certain clinical situations where in-homogeneity may be desirable. Tumors containing heterogeneous group of cell population may benefit by delivering higher dose to the areas where there is increased density of malignant cells or there are pockets containing resistant cells. Non-homogenous dose with higher central dose may improve local control in such cases; however, this increased local control come with increased risk of complications. [19],[20] In certain cases, while we try to achieve homogeneity within the target volume at any cost, the system tends to dump the extra dose (hot spot) outside the target to improve the HI, which may prove detrimental. In cases such as SRS, in which the target may lie in very close proximity to a critical organ or nerve (acoustic neuroma), very high hot spots outside the PTV potentially increases the risk of complication. [21] The importance of dose homogeneity in biologically optimized IMRT plans is controversial because if eventually the plan quality is judged by predicted biological outcome, it may no longer be required to keep the dose to target volumes as homogeneous as possible at all cost. [18] Moreover, dosimetric priorities are not the same for benign and malignant lesions. In benign lesions, heterogeneity may be acceptable in order to save the critical structure lying close to the target volume.

Thus, HI should not be seen as a tool which can replace the utility of checking the plan slice by slice for detecting and unreasonable high or low dose points. It should only be used once a satisfactory plan has been achieved on the basis of dose gradients and dose distribution along the treatment volumes and normal structures.

There is thus no consensus about the acceptable limit of HI. A value of less than 2.0 (RTOG/Formula E) is felt to balance the risk of local failure and neurologic injury (RTOG guidelines). [1] Although in our study no limitation was placed on the target volume or location of tumor in the close proximity to critical structures, a value of less than 2.0 was achieved in majority of the cases.

   Conclusion Top

Our analysis shows a reasonably high level of agreement or concordance between different formulae used for calculating the HI. This holds more significance for the formulae which accounts for the prescribed dose in denominator. It suggests that any of the described formulae may be used to calculate the HI for a particular case, provided the mentioned factors are kept in mind.

Statistically, although the study suggested that the HI index is independent of the location and the treatment volume, the trend towards an improved HI in cases with higher prescribed dose warrants further studies, with large number of patients, which may throw some more light in proving or refuting such type of association. Moreover, prospective studies with a long follow up may establish relationship between these parameters and clinical outcomes.

The literature review also suggests that although the HI is a good indicator of the quality of a plan, the analyses of DVHs and CT sections still remains an integral part of treatment plan evaluation till the ideal HI is discovered.

   References Top

1.Shaw E, Kline R, Gillin M, Souhami L, Hirschfeld A, Dinapoli R, et al. Radiation Therapy Oncology Group: Radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys 1993;27:1231-9.  Back to cited text no. 1
2.Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index- a review. Int J Radiat Oncol Biol Phys 2006;64:333-42.  Back to cited text no. 2
3.Gong Y, Wang J, Bai S, Jiang X, Xu F. Conventionally-fractionated image-guided intensity modulated radiotherapy (IG-IMRT): A safe and effective treatment for cancer spinal metastasis. Radiat oncol 2008;3:11.  Back to cited text no. 3
4.Wu Q, Mohan R, Morris M, Lavue A, Schmidt-Ullrich R. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: Dosimetric results. Int J Radiat Oncol Biol Phys 2003;26:573-85.  Back to cited text no. 4
5.Wagner TH, Bova FJ, Friedman WA, Buatti JM, Bouchet LG, Meeks SL. A simple and reliable index for scoring rival stereotactic radiosurgery plans. Int J Radiat Oncol Biol Phys 2003;57:1141-9.  Back to cited text no. 5
6.Lomax NJ, Scheib SG. Quantifying the degree of conformity in radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 2003;55:1409-19.  Back to cited text no. 6
7.Bova FJ, Meeks SA, Friedman WA. Stereotactic plan evaluation tool "the UF index". Int J Radiat Oncol Biol Phys1999;45:188.  Back to cited text no. 7
8.Van't Riet A, Mak AC, Moerland MA, Elders LH. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: Application to the prostate. Int J Radiat Oncol Biol Phys 1997;37:731-6.  Back to cited text no. 8
9.Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys 1998;40:515-24.  Back to cited text no. 9
10.ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda,MD,International Commission on Radiation Units and Measurements,1993,pp1-72  Back to cited text no. 10
11.Semerenko VA, Reitz B, Day E, Qi XS, Miften M, Li XA. Evaluation of a commercial biologically based IMRT treatment planning system. Med Phys 2008;35:5851-60.  Back to cited text no. 11
12.Collins SP, Coppa ND, Zhang Y, Collins BT, McRae DA, Jean WC. Cyberknife radiosurgery in the treatment of complex skull base tumors: Analysis of treatment planning parameters. Radiat Oncol 2006;1:46.  Back to cited text no. 12
13.Knoos T, Kristensen I, Nilsson P. Volumetric and dosimetric evaluation of radiation treatment plans: Radiation conformity index. Int J Radiat Oncol Biol Phys 1998;42:1169-76.  Back to cited text no. 13
14.Wu VW, Kwong DL, Sham JS. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2004;71:201-6.  Back to cited text no. 14
15.Wu QR, Wessels BW, Einstein DB, Maciunas RJ, Kim EY, Kinsella TJ. Quality of coverage: Conformity measures for stereotactic Radiosurgery. J Appl Clin Med Phys 2003;4:374-81.  Back to cited text no. 15
16.Yu C, Jozsef G, Apuzzo ML, Petrovich Z. Dosimetric comparison of cyberKnife with other radiosurgical modalities for an ellipsoidal target. Neurosurgery 2003;53:1155-62; discussion 1162-3.  Back to cited text no. 16
17.Chang SD, Gibbs IC, Sakamoto GT, Lee E, Oyelese A, Adler JR. Staged stereotactic irradiation for acoustic neuroma. Neurosurgery 2005;56:1254-61; discussion 1261-3.  Back to cited text no. 17
18.Wang X, Zhang X, Dong L, Liu H, Gillin M, Ahamad A, et al. Effectiveness of noncoplaner IMRT planning using a parallelized multiresolution beam angle optimization method for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2005;63:594-601.  Back to cited text no. 18
19.Dejean C, Lefkopoulos D, Foulquier JN, Schlienger M, Touboul E. Automatic definition of prescription isodose for stereotaxic radiation of arterio-venous malformations. Cancer Radiother 2001;5:138-49.  Back to cited text no. 19
20.Grandjean P, Platoni K, Lefkopoulos D, Merienne L, Schlienger M. Use of a general inverse technique for the conformational stereotactic treatment of complex intracranial lesions. Int J Radiat Oncol Biol Phys 1998;41:69-76.  Back to cited text no. 20
21.Akpati H, Kim CS, Kim B, Park T, Meek A. Unified dosimetry index (UDI): A figure of merit for ranking treatment plans. J Appl Clin Med Phys 2008;9:2803.  Back to cited text no. 21


  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]

This article has been cited by
1 Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy
Mümtaz Köksal, Laura Kersting, Felix Schoroth, Stephan Garbe, David Koch, Davide Scafa, Gustavo R. Sarria, Christina Leitzen, Annkristin Heine, Tobias Holderried, Peter Brossart, Eleni Zoga, Ulrike Attenberger, Leonard C. Schmeel
Journal of Cancer Research and Clinical Oncology. 2023;
[Pubmed] | [DOI]
2 Comparison of intensity-modulated radiation therapy (IMRT), 3D conformal proton therapy and intensity-modulated proton therapy (IMPT) for the treatment of metastatic brain cancer
Matthew Sullivan, Hosang Jin, Salahuddin Ahmad
Medical Dosimetry. 2023;
[Pubmed] | [DOI]
3 For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes
Crystal Seldon Taswell, Matthew Studenski, Thomas Pennix, Bryan Stover, Mike Georgiou, Shree Venkat, Patricia Jones, Joseph Zikria, Lindsay Thornton, Raphael Yechieli, Prasoon Mohan, Lorraine Portelance, Benjamin Spieler
Cancers. 2023; 15(3): 645
[Pubmed] | [DOI]
4 Multi-Planar VMAT Plans for High-Grade Glioma and Glioblastoma Targeting the Hypothalamic-Pituitary Axis Sparing
Eva Y. W. Cheung, Shirley S. H. Ng, Sapphire H. Y. Yung, Dominic Y. T. Cheng, Fandy Y. C. Chan, Janice K. Y. Cheng
Life. 2022; 12(2): 195
[Pubmed] | [DOI]
Anjana A K, Silambarasan N S, Jitendra Nigam, Navitha S, Piyush Kumar
[Pubmed] | [DOI]
6 Transition from 3D conformal to modern modulated craniospinal radiotherapy
Hamida Fakira, Thurandrie Naiker, Brendon Smith, Annemari Groenewald
South African Journal of Oncology. 2022; 6
[Pubmed] | [DOI]
7 Dr. Kanhu’s COSID index: An acronym for plan evaluation in SRS & SBRT
KanhuCharan Patro, Ajitesh Avinash, Arya Pradhan, Chittaranjan Kundu, ParthaSarathi Bhattacharyya, VenkataKrishna Reddy Pilaka, Mrityunjaya Muvvala, Arunachalam Chithambara, AyyalasomayajulaAnil Kumar, Srinu Aketi, Parasa Prasad, VenkataNaga Priyasha Damodara, VeeraSurya Premchand Kumar Avidi, Mohanapriya Atchaiyalingam, Keerthiga Karthikeyan
Journal of Current Oncology. 2022; 5(1): 4
[Pubmed] | [DOI]
8 Dosimetric evaluation of different radiotherapy techniques in mastectomized left-sided breast cancer
Nezahat Olacak, YusufZiya Hazeral, Burçin Hazeral, Ozge Duran, Gülay Güray, Senem Alanyali, Ayfer Haydaroglu
Journal of Cancer Research and Therapeutics. 2022; 0(0): 0
[Pubmed] | [DOI]
9 Validation of RapidPlan knowledge-based model for volumetric-modulated arc therapy in prostate cancer
IsraIsrangkul Na Ayuthaya, Sivalee Suriyapee, Taweap Sanghangthum
Journal of Medical Physics. 2022; 47(3): 250
[Pubmed] | [DOI]
10 Dosimetric advantages of volumetric modulated arc therapy (VMAT) with deep inspiration breath hold (DIBH) technique in Halcyon Linac for left breast cancer treatment
Alex Pui-yin Cheung, Michelle Man-i Lei, Sau-sing Lee, Wai-ki Hung, Chun-wang Chiu, Xi-bin Qiu, Ricky Ming-chun Chau
Medical Dosimetry. 2022;
[Pubmed] | [DOI]
11 Dosimetric comparison of analytical anisotropic algorithm and the two dose reporting modes of Acuros XB dose calculation algorithm in volumetric modulated arc therapy of carcinoma lung and carcinoma prostate
Zhenia Gopalakrishnan, Saju Bhasi, Raghukumar P., Sharika V. Menon, Sarin B., Anna George Thayil, Raghuram K. Nair
Medical Dosimetry. 2022;
[Pubmed] | [DOI]
12 nTMS-derived DTI-based motor fiber tracking in radiotherapy treatment planning of high-grade gliomas for avoidance of motor structures
C.D. Diehl, E. Rosenkranz, M. Mißlbeck, M. Schwendner, N. Sollmann, S. Ille, B. Meyer, S.E. Combs, D. Bernhardt, S.M. Krieg
Radiotherapy and Oncology. 2022;
[Pubmed] | [DOI]
13 Klinik und Versorgung von radiogenen Behandlungsnebenwirkungen am Auge
Andrea M. Klassen, Michael Zimbelmann, Sabine Lüken, Florian Cremers, Dirk Rades, Argyrios Chronopoulos, Felix Rommel, Mahdy Ranjbar, Salvatore Grisanti, Vinodh Kakkassery
Die Ophthalmologie. 2022;
[Pubmed] | [DOI]
14 Is there a dosimetric advantage of volumetric modulated arc therapy over intensity modulated radiotherapy in head and neck cancer?
Nikolett Buciuman, Loredana G. Marcu
European Archives of Oto-Rhino-Laryngology. 2022;
[Pubmed] | [DOI]
15 Comprehensive evaluation of dosimetric impact against position errors in accelerator-based BNCT under different treatment parameter settings
Ryo Kakino, Naonori Hu, Kayako Isohashi, Teruhito Aihara, Keiji Nihei, Koji Ono
Medical Physics. 2022;
[Pubmed] | [DOI]
16 Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience
Cristiana Pedone, Bruno Sorcini, Caroline Staff, Johanna Färlin, Tone Fokstuen, Jan-Erik Frödin, Per J. Nilsson, Anna Martling, Alexander Valdman
Clinical and Translational Radiation Oncology. 2022; : 100562
[Pubmed] | [DOI]
17 Planning evaluation of a novel volume-based algorithm for personalized optimization of lung dose in VMAT for esophageal cancer
Chen-Xiong Hsu, Kuan-Heng Lin, Shan-Ying Wang, Wei-Ta Tsai, Chiu-Han Chang, Hui-Ju Tien, Pei-Wei Shueng, Tung-Hsin Wu, Greta S. P. Mok
Scientific Reports. 2022; 12(1)
[Pubmed] | [DOI]
18 Outcome of stereotactic body radiation for treatment of nasal and nasopharyngeal lymphoma in 32 cats
Alicja I. Reczynska, Susan M. LaRue, Mary-Keara Boss, Ber-In Lee, Del Leary, Kelsey Pohlmann, Lynn Griffin, Susan Lana, Tiffany Wormhoudt Martin
Journal of Veterinary Internal Medicine. 2022;
[Pubmed] | [DOI]
19 Comparison of Absolute Dose Achievable Between Helical Tomotherapy and RapidArc in Total Dura Mater Irradiation for Child Cancer
Wenzhao Sun, Jun Zhang, Yixuan Wang, Meining Chen, Jianli Wang, Li Chen, Lixia Lu, Xiaowu Deng
Technology in Cancer Research & Treatment. 2022; 21: 1533033821
[Pubmed] | [DOI]
20 Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial
Thomas Held, Thomas Tessonnier, Henrik Franke, Sebastian Regnery, Lukas Bauer, Katharina Weusthof, Semi Harrabi, Klaus Herfarth, Andrea Mairani, Jürgen Debus, Sebastian Adeberg
Radiation Oncology. 2022; 17(1)
[Pubmed] | [DOI]
21 Assessment of IMPT versus VMAT plans using different uncertainty scenarios for prostate cancer
Michael P. Butkus, Nellie Brovold, Tejan Diwanji, Yihang Xu, Mariluz De Ornelas, Alan Dal Pra, Matt Abramowitz, Alan Pollack, Nesrin Dogan
Radiation Oncology. 2022; 17(1)
[Pubmed] | [DOI]
22 Helical versus static approaches to delivering tomotherapy to the junctional target for patients taller than 135 cm undergoing total body irradiation
Mümtaz Köksal, Jonathan Baumert, Felix Schoroth, Thomas Müdder, Davide Scafa, David Koch, Christina Leitzen, Gustavo R. Sarria, Leonard C. Schmeel, Frank A. Giordano
European Journal of Medical Research. 2022; 27(1)
[Pubmed] | [DOI]
23 Lung sparing and ribcage coverage in total body irradiation delivered by helical tomotherapy
Mümtaz Köksal, Jonathan Baumert, Felix Schoroth, Davide Scafa, David Koch, Christina Leitzen, Gustavo R. Sarria, Frank A. Giordano, Georgios Chatzikonstantinou, Leonard C. Schmeel
European Journal of Medical Research. 2022; 27(1)
[Pubmed] | [DOI]
24 Comparison of Dose Statistics of Intensity-Modulated Radiation Therapy Plan from Varian Eclipse Treatment Planning System with Novel Python-Based Indigenously Developed Software
Sougoumarane Dashnamoorthy, Karthick Rajamanickam, Ebenezar Jeyasingh, Vindhyavasini Prasad Pandey, Kathiresan Nachimuthu, Imtiaz Ahmed, Pitchaikannu Venkatraman
Progress in Medical Physics. 2022; 33(3): 25
[Pubmed] | [DOI]
25 Dosimetric Evaluation of Synthetic Computed Tomography Technique on Position Variation of Air Cavity in Magnetic Resonance-Guided Radiotherapy
Hyeongmin Jin, Hyun Joon An, Eui Kyu Chie, Jong Min Park, Jung-in Kim
Progress in Medical Physics. 2022; 33(4): 142
[Pubmed] | [DOI]
26 Dosimetric comparison of mDCAT and VMAT techniques according to 6MV-FFF and 10MV-FFF energies in patients with single adrenal metastasis
Ismail Faruk Durmus, Ayse Okumus
Journal of X-Ray Science and Technology. 2022; : 1
[Pubmed] | [DOI]
27 Quantitative Comparison of Knowledge-Based and Manual Intensity Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma
Jiang Hu, Boji Liu, Weihao Xie, Jinhan Zhu, Xiaoli Yu, Huikuan Gu, Mingli Wang, Yixuan Wang, ZhenYu Qi
Frontiers in Oncology. 2021; 10
[Pubmed] | [DOI]
28 Comparison of helical tomotherapy with multi-field intensity-modulated radiotherapy treatment plans using simultaneous integrated boost in high-risk prostate cancer
Hamit Basaran, Sibel Karaca, Timur Koca, Yasemin Örs Gündogdu
Polish Journal of Medical Physics and Engineering. 2021; 27(2): 143
[Pubmed] | [DOI]
29 Non-coplanar VMAT plans for postoperative primary brain tumour to reduce dose to hippocampus, temporal lobe and cochlea: a planning study
Eva Yi Wah Cheung, Kevin Ho Yuen Lee, Wilson Tin Long Lau, Amy Pik Yan Lau, Pak Ying Wat
BJR|Open. 2021; 3(1): 20210009
[Pubmed] | [DOI]
30 Formulation of Medicated Chewing Gum Containing Sceletium tortuosum and Process Optimization Utilizing the SeDeM Diagram Expert System
Joe M. Viljoen, Sonja van der Walt, Josias H. Hamman
AAPS PharmSciTech. 2021; 22(3)
[Pubmed] | [DOI]
31 Comparative study of the collapsed cone convolution and Monte Carlo algorithms for radiation therapy planning of canine sinonasal tumors reveals significant dosimetric differences
Ber-In Lee, Mary-Keara Boss, Susan M. LaRue, Tiffany Martin, Del Leary
Veterinary Radiology & Ultrasound. 2021;
[Pubmed] | [DOI]
32 Evaluation of VMAT Planning Strategies for Prostate Patients with Bilateral Hip Prosthesis
David To, Ilma Xhaferllari, Manju Liu, Jian Liang, Cory Knill, Sirisha Nandalur, Gary Gustafson, Danielle Lack
Technology in Cancer Research & Treatment. 2021; 20: 1533033821
[Pubmed] | [DOI]
33 The Capabilities and Characteristics of Helical Tomotherapy and Co-Planar Dual Arcs Volumetric-Modulated arc Therapy Associated with Hippocampal Sparing During Prophylactic Cranial Irradiation
Dandan Wang, Xingmin Ma, Lu Fu, Jiabing Gu, Tong Bai, Yong Yin, Baosheng Li, Jian Zhu
Technology in Cancer Research & Treatment. 2021; 20: 1533033821
[Pubmed] | [DOI]
34 Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer
Zhi-tao Dai, Li Ma, Ting-ting Cao, Lian Zhu, Man Zhao, Ning Li
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
35 Pareto Optimal Projection Search (POPS): Automated Radiation Therapy Treatment Planning by Direct Search of the Pareto Surface
Charles Huang, Yong Yang, Neil Panjwani, Stephen Boyd, Lei Xing
IEEE Transactions on Biomedical Engineering. 2021; 68(10): 2907
[Pubmed] | [DOI]
36 Comparison of dose volumetric parameters of oesophagus in the radiation treatment of carcinoma breast with and without oesophagus delineation
Reshma Bhaskaran, Sajeev George Pulickal, Harikrishnan Reghu, Aparna Perumangat, Girish Babu Moolath
Journal of Radiotherapy in Practice. 2021; : 1
[Pubmed] | [DOI]
37 Impact of Multiple Beams on Plan Quality, Linear Energy Transfer Distribution, and Plan Robustness of Intensity Modulated Proton Therapy for Lung Cancer
Haijiao Shang, Yuehu Pu, Zhiling Chen, Xuetao Wang, Cuiyun Yuan, Xiance Jin, Chenbin Liu
ACS Sensors. 2021; 6(2): 408
[Pubmed] | [DOI]
38 Learning-based dose prediction for pancreatic stereotactic body radiation therapy using dual pyramid adversarial network
Shadab Momin, Yang Lei, Tonghe Wang, Jiahan Zhang, Justin Roper, Jeffrey D Bradley, Walter J Curran, Pretesh Patel, Tian Liu, Xiaofeng Yang
Physics in Medicine & Biology. 2021; 66(12): 125019
[Pubmed] | [DOI]
39 A systematically compiled set of quantitative metrics to describe spatial characteristics of radiotherapy dose distributions and aid in treatment planning
Laura Patricia Kaplan, Stine Sofia Korreman
Physica Medica. 2021; 90: 164
[Pubmed] | [DOI]
40 A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients
N. Khalladi, C. Dejean, M. Bosset, Y. Pointreau, R. Kinj, S. Racadot, J. Castelli, F. Huguet, S. Renard, S. Guihard, Y. Tao, J.M. Rouvier, A. Johnson, J. Bourhis, S. Xu Shan, J. Thariat
Cancer/Radiothérapie. 2021; 25(8): 755
[Pubmed] | [DOI]
41 Explication of absorbed dose defines radiotherapy – A study of unification
Rangaraj Bhattacharjee, Lakshmi K. Singh, Ananya Bhattacharjee
Materials Today: Proceedings. 2021; 46: 6335
[Pubmed] | [DOI]
42 Efficacy of MLC based cobalt-60 plans: A DVH comparison and analysis with 6 MV plans
Akula Roopa Rani, Komanduri Ayyangar, A.R. Reddy, Ayyalasomayajula Anil Kumar, Pal Reddy Yadagiri Reddy
Medical Dosimetry. 2021; 46(1): 80
[Pubmed] | [DOI]
43 Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison
My-Lien Nguyen, J. Nathan Cantrell, Salahuddin Ahmad, Christina Henson
Medical Dosimetry. 2021; 46(3): 259
[Pubmed] | [DOI]
44 Evaluation of automatic VMAT plans in locally advanced nasopharyngeal carcinoma
Quanbin Zhang, Liya Ou, Yingying Peng, Hui Yu, Linjing Wang, Shuxu Zhang
Strahlentherapie und Onkologie. 2021; 197(3): 177
[Pubmed] | [DOI]
45 Total body irradiation of bone marrow transplant using helical TomoTherapy with a focus on the quality of dose contribution at junction target volumes
N. V. N. Madhusudhana Sresty, Deleep Gudipudi, A. Krishnam Raju, T. Anil kumar, V. R. P. Lakshmi, G. Srikanth, M. Narasimha
Strahlentherapie und Onkologie. 2021; 197(8): 722
[Pubmed] | [DOI]
46 An updating approach for knowledge-based planning models to improve plan quality and variability in volumetric-modulated arc therapy for prostate cancer
Kenji Nakamura, Katsuya Okuhata, Mikoto Tamura, Masakazu Otsuka, Kazuki Kubo, Yoshihiro Ueda, Yasunori Nakamura, Kiyoshi Nakamatsu, Masao Tanooka, Hajime Monzen, Yasumasa Nishimura
Journal of Applied Clinical Medical Physics. 2021; 22(9): 113
[Pubmed] | [DOI]
47 Stereotactic radiotherapy for small and very small tumours (=1 to =3 cc): evaluation of the influence of volumetric-modulated arc therapy in comparison to dynamic conformal arc therapy and 3D conformal radiotherapy as a function of flattened and unflatten
Gopinath Mamballikalam, S. Senthilkumar, R. C. Jaon Bos, P. M. Ahamed Basith, P. M. Jayadevan
Journal of Radiotherapy in Practice. 2021; 20(1): 59
[Pubmed] | [DOI]
48 Dosimetric comparison of RapidPlan and manually optimised volumetric modulated arc therapy plans in prostate cancer
Loyce M. H. Chua, Eric P. P. Pang, Zubin Master, Rehena Sultana, Jeffrey K. L. Tuan, Christopher M. Bragg
Journal of Radiotherapy in Practice. 2021; 20(3): 257
[Pubmed] | [DOI]
49 Dosimetric comparison of helical tomotherapy and hybrid (3DCRT-VMAT) technique for locally advanced non-small cell lung cancer
Öztun Temelli, Mehmet Demirtas, Berat Tugrul Ugurlu
Journal of Radiotherapy in Practice. 2021; 20(3): 300
[Pubmed] | [DOI]
50 Patient-Specific Heart Constraint: A Tool for Optimization and Evaluation of Mean Heart Dose in Breast Cancer Patients
Rachel Ward, Katrina West, Drew Latty, Rachael Beldham-Collins, Dan Jia, Wei Wang, Shamira Cross, Val Gebski, Verity Ahern, Kirsty Stuart
Practical Radiation Oncology. 2021; 11(2): e154
[Pubmed] | [DOI]
51 Technical Report: Development and Implementation of an Open Source Template Interpretation Class Library for Automated Treatment Planning
Matthew C. Schmidt, Eleanor A. Pryser, Brian C. Baumann, Mahmoud M. Yaqoub, Caleb A. Raman, Peter Szentivanyi, Jeff M. Michalski, Hiram A. Gay, Nels C. Knutson, Geoffrey Hugo, Erno Sajo, Piotr Zygmanski, Thomas Mazur, Joseph Dise, Jochen Cammin, Eric Laugeman, Francisco J. Reynoso
Practical Radiation Oncology. 2021;
[Pubmed] | [DOI]
52 Postoperative radiotherapy with intensity-modulated radiation therapy versus 3-dimensional conformal radiotherapy in early breast cancer: A randomized clinical trial of KROG 15-03
Kyu Hye Choi, Sung Ja Ahn, Jae Uk Jeong, Mina Yu, Jin Hee Kim, Bae Kwon Jeong, Joo Hwan Lee, Sung Hwan Kim, Jong Hoon Lee
Radiotherapy and Oncology. 2021; 154: 179
[Pubmed] | [DOI]
53 Plan quality effects of maximum monitor unit constraints in pencil beam scanning proton therapy for central nervous system and skull base tumors
Avani Dholakia Rao, Kai Sun, Mingyao Zhu, Sina Mossahebi, Pouya Sabouri, Thomas Houser, Jenna Jatczak, Mark Zakhary, William F. Regine, Robert C. Miller, Søren Bentzen, Mark V. Mishra
Radiotherapy and Oncology. 2021; 160: 18
[Pubmed] | [DOI]
54 Modified VMAT Plans for Locally Advanced Centrally Located Non-Small Cell Lung Cancer (NSCLC)
Eva Y. W. Cheung, Virginia H. Y. Kwong, Fandy Y. C. Chan, Dominic Y. T. Cheng, Janice K. Y. Cheng, Sapphire H. Y. Yung, Kiris T. K. Chan, Kelly T. Y. Cheung, Tracy S. W. Cheung, Janna C. L. Yiu
Life. 2021; 11(10): 1085
[Pubmed] | [DOI]
55 A Modular System for Treating Moving Anatomical Targets With Scanned Ion Beams at Multiple Facilities: Pre-Clinical Testing for Quality and Safety of Beam Delivery
Michelle Lis, Wayne Newhauser, Marco Donetti, Moritz Wolf, Timo Steinsberger, Athena Paz, Marco Durante, Christian Graeff
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
56 Knowledge-Based Planning for Robustly Optimized Intensity-Modulated Proton Therapy of Head and Neck Cancer Patients
Yihang Xu, Jonathan Cyriac, Mariluz De Ornelas, Elizabeth Bossart, Kyle Padgett, Michael Butkus, Tejan Diwanji, Stuart Samuels, Michael A. Samuels, Nesrin Dogan
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
57 A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam
Arthur Bongrand, Charbel Koumeir, Daphnée Villoing, Arnaud Guertin, Ferid Haddad, Vincent Métivier, Freddy Poirier, Vincent Potiron, Noël Servagent, Stéphane Supiot, Grégory Delpon, Sophie Chiavassa
Cancers. 2021; 13(8): 1889
[Pubmed] | [DOI]
58 Dosimetric comparison of coplanar and non-coplanar volumetric-modulated arc therapy in head and neck cancer treated with radiotherapy
Sanjib Gayen, Sri Harsha Kombathula, Sumanta Manna, Sonal Varshney, Puneet Pareek
Radiation Oncology Journal. 2020; 38(2): 138
[Pubmed] | [DOI]
59 Predictive factors for local control of early glottic squamous cell carcinomas after definitive radiotherapy
Mitsuru Okubo, Tomohiro Itonaga, Tatsuhiko Saito, Sachika Shiraishi, Ryuji Mikami, Akira Sakurada, Shinji Sugahara, Jinho Park, Koichi Tokuuye, Kazuhiro Saito
Molecular and Clinical Oncology. 2020;
[Pubmed] | [DOI]
60 Comparison of O-ring and General Linacs for Treatment Planning of Volumetric Modulated Arc Therapy
Kenji Matsumoto, Masakazu Otsuka, Mikoto Tamura, Hajime Monzen, Masahiko Okumura
Japanese Journal of Radiological Technology. 2020; 76(4): 339
[Pubmed] | [DOI]
61 Surface mould brachytherapy planning in giant cell tumour of the tendon sheath of finger and dosimetric comparison with external beam radiotherapy: a case report
Anil Gupta, Rambha Pandey, Anant Krishna, Rishabh Kumar, Seema Sharma, Rashmi Sarawagi, Kanika Garg
Journal of Radiotherapy in Practice. 2020; : 1
[Pubmed] | [DOI]
62 The role of breath hold intensity modulated proton therapy for a case of left-sided breast cancer with IMN involvement. How protons compare with other conformal techniques?
H.L. Lee, L.H. Lim, Zubin Master, Sharon M.M. Wong
Technical Innovations & Patient Support in Radiation Oncology. 2020; 15: 1
[Pubmed] | [DOI]
63 Mitigation of motion effects in pencil-beam scanning – Impact of repainting on 4D robustly optimized proton treatment plans for hepatocellular carcinoma
Hilda Siregar, Christian Bäumer, Oliver Blanck, Mark Chan, Erik Engwall, Sandija Plaude, Bernhard Spaan, Beate Timmermann, Jörg Wulff
Zeitschrift für Medizinische Physik. 2020;
[Pubmed] | [DOI]
64 Dosimetric impact of geometric distortions in an MRI-only proton therapy workflow for lung, liver and pancreas
Hatice Selcen Dumlu, Giorgia Meschini, Christopher Kurz, Florian Kamp, Guido Baroni, Claus Belka, Chiara Paganelli, Marco Riboldi
Zeitschrift für Medizinische Physik. 2020;
[Pubmed] | [DOI]
65 Trajectory-based VMAT for cranial targets with delivery at shortened SAD
Joel Mullins, Marc-André Renaud, Veng Heng, Russell Ruo, François DeBlois, Jan Seuntjens
Medical Physics. 2020; 47(7): 3103
[Pubmed] | [DOI]
66 Can Conformity-Based Volumetric Modulated Arc Therapy Improve Dosimetry and Speed of Delivery in Radiation Therapy to Lumbosacral Spine Compared with Conventional Techniques?
Joanna Javor, Meagan Robbins, Tara Rosewall, Tim Craig, Conrad Joseph Villafuerte, Bernard Cummings, Laura Dawson
Journal of Medical Imaging and Radiation Sciences. 2020; 51(3): 404
[Pubmed] | [DOI]
67 A retrospective analysis of stereotactic body radiation therapy for canine heart base tumors: 26 cases
C.R. Kruckman-Gatesy, M.K. Ames, L.R. Griffin, M.-K. Boss, S. Rao, D. Leary, S.M. LaRue
Journal of Veterinary Cardiology. 2020; 27: 62
[Pubmed] | [DOI]
68 Comparaison entre Stump Cylinder et moule personnalisé, effet de la forme de l’applicateur sur la distribution de dose
M. Jreij, Z. Al Kattar, J. Charara
Cancer/Radiothérapie. 2020; 24(2): 106
[Pubmed] | [DOI]
69 Constrained optimization towards marker-based tumor tracking in VMAT
Azeez Omotayo, Sankar Venkataraman, Boyd McCurdy
Biomedical Physics & Engineering Express. 2020; 7(1): 015011
[Pubmed] | [DOI]
70 Predicting radiation treatment planning evaluation parameter using artificial intelligence and machine learning
Frederick Ng, Runqing Jiang, James C L Chow
IOP SciNotes. 2020; 1(1): 014003
[Pubmed] | [DOI]
71 Dose–volume histogram analysis and clinical evaluation of knowledge-based plans with manual objective constraints for pharyngeal cancer
Takuya Uehara, Hajime Monzen, Mikoto Tamura, Kazuki Ishikawa, Hiroshi Doi, Yasumasa Nishimura
Journal of Radiation Research. 2020; 61(3): 499
[Pubmed] | [DOI]
72 Application of 3D-print silica bolus for nasal NK/T-cell lymphoma radiation therapy
Guyu Dai, Xin Xu, Xiaohong Wu, Xiaolin Lei, Xing Wei, Zhibin Li, Qing Xiao, Renming Zhong, Sen Bai
Journal of Radiation Research. 2020; 61(6): 920
[Pubmed] | [DOI]
73 Secondary cancer risk after radiation therapy for breast cancer with different radiotherapy techniques
Quanbin Zhang, Jinbo Liu, Ningjian Ao, Hui Yu, Yingying Peng, Liya Ou, Shuxu Zhang
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
74 Safety and efficacy of stereotactic body radiation therapy ( SBRT ) for the treatment of canine thyroid carcinoma
Ber-In Lee, Susan M. LaRue, Bernard Seguin, Lynn Griffin, Amber Prebble, Tiffany Martin, Del Leary, Mary-Keara Boss
Veterinary and Comparative Oncology. 2020; 18(4): 843
[Pubmed] | [DOI]
75 Appropriate reduction of the fragmentation level of subfield sequences to improve the accuracy of field delivery in IMRT for nasopharyngeal carcinoma
Yanze Sun, Gang Zhou, Yaqun Zhu, Li Zou, Ye Tian
The British Journal of Radiology. 2020; 93(1109): 20190767
[Pubmed] | [DOI]
76 Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients
Laila König, Matthias F. Häfner, Sonja Katayama, Stefan A. Koerber, Eric Tonndorf-Martini, Denise Bernhardt, Bastian von Nettelbladt, Fabian Weykamp, Philipp Hoegen, Sebastian Klüter, Matthew S. Susko, Jürgen Debus, Juliane Hörner-Rieber
Radiation Oncology. 2020; 15(1)
[Pubmed] | [DOI]
77 Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung
Philipp Hoegen, Clemens Lang, Sati Akbaba, Peter Häring, Mona Splinter, Annette Miltner, Marion Bachmann, Christiane Stahl-Arnsberger, Thomas Brechter, Rami A. El Shafie, Fabian Weykamp, Laila König, Jürgen Debus, Juliane Hörner-Rieber
Frontiers in Oncology. 2020; 10
[Pubmed] | [DOI]
78 Comparison of Different Combinations of Irradiation Mode and Jaw Width in Helical Tomotherapy for Nasopharyngeal Carcinoma
Jun Zhang, Yinglin Peng, Shouliang Ding, Jinhan Zhu, Yimei Liu, Meining Chen, Wenzhao Sun, Linghong Zhou, Xiaowu Deng
Frontiers in Oncology. 2020; 10
[Pubmed] | [DOI]
Flowerlit Thomas, Suresh Kumar K, Mintu Mathew, Kiran P
Journal of Evolution of Medical and Dental Sciences. 2019; 8(1): 62
[Pubmed] | [DOI]
80 Oxygen-Guided Radiation Therapy
Boris Epel, Matthew C. Maggio, Eugene D. Barth, Richard C. Miller, Charles A. Pelizzari, Martyna Krzykawska-Serda, Subramanian V. Sundramoorthy, Bulent Aydogan, Ralph R. Weichselbaum, Victor M. Tormyshev, Howard J. Halpern
International Journal of Radiation Oncology*Biology*Physics. 2019; 103(4): 977
[Pubmed] | [DOI]
81 Fluence-map generation for prostate intensity-modulated radiotherapy planning using a deep-neural-network
Hoyeon Lee, Hojin Kim, Jungwon Kwak, Young Seok Kim, Sang Wook Lee, Seungryong Cho, Byungchul Cho
Scientific Reports. 2019; 9(1)
[Pubmed] | [DOI]
82 Complementary Relation Between the Improvement of Dose Delivery Technique and PTV Margin Reduction in Dose-Escalated Radiation Therapy for Prostate Cancer
Satoru Utsunomiya, Jun Yamamoto, Satoshi Tanabe, Mayu Oishi, Aruha Satsuma, Motoki Kaidu, Eisuke Abe, Atsushi Ohta, Naotaka Kushima, Hidefumi Aoyama
Practical Radiation Oncology. 2019; 9(3): 172
[Pubmed] | [DOI]
83 Dosimetric comparison of five different techniques for craniospinal irradiation across 15 European centers: analysis on behalf of the SIOP-E-BTG (radiotherapy working group)
Enrica Seravalli, Mirjam Bosman, Yasmin Lassen-Ramshad, Anne Vestergaard, Foppe Oldenburger, Jorrit Visser, Efi Koutsouveli, Chryssa Paraskevopoulou, Gail Horan, Thankamma Ajithkumar, Beate Timmermann, Carolina-Sofia Fuentes, Gillian Whitfield, Thomas Marchant, Laetitia Padovani, Eloise Garnier, Lorenza Gandola, Silvia Meroni, Bianca A. W. Hoeben, Martijn Kusters, Claire Alapetite, Sandra Losa, Farid Goudjil, Henriette Magelssen, Morten Egeberg Evensen, Frank Saran, Gregory Smyth, Barbara Rombi, Roberto Righetto, Rolf-Dieter Kortmann, Geert O. Janssens
Acta Oncologica. 2018; 57(9): 1240
[Pubmed] | [DOI]
84 Dosimetric comparison of the helical tomotherapy, volumetric-modulated arc therapy and fixed-field intensity-modulated radiotherapy for stage IIB-IIIB non-small cell lung cancer
Yujin Xu, Weiye Deng, Shuangyan Yang, Pu Li, Yue Kong, Ye Tian, Zhongxing Liao, Ming Chen
Scientific Reports. 2017; 7(1)
[Pubmed] | [DOI]
85 Superiority in Robustness of Multifield Optimization Over Single-Field Optimization for Pencil-Beam Proton Therapy for Oropharynx Carcinoma: An Enhanced Robustness Analysis
Kristin Stützer, Alexander Lin, Maura Kirk, Liyong Lin
International Journal of Radiation Oncology*Biology*Physics. 2017; 99(3): 738
[Pubmed] | [DOI]
86 The Impact of Body Mass Index on Radiotherapy Technique in Patients With Early-Stage Endometrial Cancer
Guler Yavas,Cagdas Yavas,Ozlem Secilmis Kerimoglu,Cetin Celik
International Journal of Gynecological Cancer. 2014; 24(9): 1607
[Pubmed] | [DOI]
87 Target splitting non-coplanar RapidArc radiation therapy for a diffuse sebaceous carcinoma of the scalp: a novel delivery technique
Jiang Hu,WeiWei Xiao,ZhiChun He,DeHua Kang,ALong Chen,ZhenYu Qi
Radiation Oncology. 2014; 9(1): 204
[Pubmed] | [DOI]
88 Comparison of proton therapy techniques for treatment of the whole brain as a component of craniospinal radiation
Jeffrey Dinh,Joshua Stoker,Rola H Georges,Narayan Sahoo,X Zhu,Smruti Rath,Anita Mahajan,David R Grosshans
Radiation Oncology. 2013; 8(1): 289
[Pubmed] | [DOI]
89 Four-dimensional radiotherapeutic dose calculation using biomechanical respiratory motion description
Petru Manescu,Hamid Ladjal,Joseph Azencot,Michael Beuve,Etienne Testa,Behzad Shariat
International Journal of Computer Assisted Radiology and Surgery. 2013;
[Pubmed] | [DOI]


Print this article  Email this article


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (343 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

    Materials and Me...
    Article Tables

 Article Access Statistics
    PDF Downloaded1316    
    Comments [Add]    
    Cited by others 89    

Recommend this journal